Drug combinations identified by high-throughput screening promote cell cycle transition and upregulate Smad pathways in myeloma
Copyright © 2023 Elsevier B.V. All rights reserved..
Drug resistance and disease progression are common in multiple myeloma (MM) patients, underscoring the need for new therapeutic combinations. A high-throughput drug screen in 47 MM cell lines and in silico Huber robust regression analysis of drug responses revealed 43 potentially synergistic combinations. We hypothesized that effective combinations would reduce MYC expression and enhance p16 activity. Six combinations cooperatively reduced MYC protein, frequently over-expressed in MM and also cooperatively increased p16 expression, frequently downregulated in MM. Synergistic reductions in viability were observed with top combinations in proteasome inhibitor-resistant and sensitive MM cell lines, while sparing fibroblasts. Three combinations significantly prolonged survival in a transplantable Ras-driven allograft model of advanced MM closely recapitulating high-risk/refractory myeloma in humans and reduced viability of ex vivo treated patient cells. Common genetic pathways similarly downregulated by these combinations promoted cell cycle transition, whereas pathways most upregulated were involved in TGFβ/SMAD signaling. These preclinical data identify potentially useful drug combinations for evaluation in drug-resistant MM and reveal potential mechanisms of combined drug sensitivity.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:568 |
|---|---|
| Enthalten in: |
Cancer letters - 568(2023) vom: 01. Aug., Seite 216284 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Peat, Tyler J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Dinaciclib |
|---|
| Anmerkungen: |
Date Completed 21.07.2023 Date Revised 09.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.canlet.2023.216284 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358578353 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358578353 | ||
| 003 | DE-627 | ||
| 005 | 20231226075040.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.canlet.2023.216284 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1195.xml |
| 035 | |a (DE-627)NLM358578353 | ||
| 035 | |a (NLM)37356470 | ||
| 035 | |a (PII)S0304-3835(23)00235-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Peat, Tyler J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Drug combinations identified by high-throughput screening promote cell cycle transition and upregulate Smad pathways in myeloma |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.07.2023 | ||
| 500 | |a Date Revised 09.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier B.V. All rights reserved. | ||
| 520 | |a Drug resistance and disease progression are common in multiple myeloma (MM) patients, underscoring the need for new therapeutic combinations. A high-throughput drug screen in 47 MM cell lines and in silico Huber robust regression analysis of drug responses revealed 43 potentially synergistic combinations. We hypothesized that effective combinations would reduce MYC expression and enhance p16 activity. Six combinations cooperatively reduced MYC protein, frequently over-expressed in MM and also cooperatively increased p16 expression, frequently downregulated in MM. Synergistic reductions in viability were observed with top combinations in proteasome inhibitor-resistant and sensitive MM cell lines, while sparing fibroblasts. Three combinations significantly prolonged survival in a transplantable Ras-driven allograft model of advanced MM closely recapitulating high-risk/refractory myeloma in humans and reduced viability of ex vivo treated patient cells. Common genetic pathways similarly downregulated by these combinations promoted cell cycle transition, whereas pathways most upregulated were involved in TGFβ/SMAD signaling. These preclinical data identify potentially useful drug combinations for evaluation in drug-resistant MM and reveal potential mechanisms of combined drug sensitivity | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Dinaciclib | |
| 650 | 4 | |a Entinostat | |
| 650 | 4 | |a MYC | |
| 650 | 4 | |a Myeloma | |
| 650 | 4 | |a p16 | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 700 | 1 | |a Gaikwad, Snehal M |e verfasserin |4 aut | |
| 700 | 1 | |a Dubois, Wendy |e verfasserin |4 aut | |
| 700 | 1 | |a Gyabaah-Kessie, Nana |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Shuling |e verfasserin |4 aut | |
| 700 | 1 | |a Gorjifard, Sayeh |e verfasserin |4 aut | |
| 700 | 1 | |a Phyo, Zaw |e verfasserin |4 aut | |
| 700 | 1 | |a Andres, Megan |e verfasserin |4 aut | |
| 700 | 1 | |a Hughitt, V Keith |e verfasserin |4 aut | |
| 700 | 1 | |a Simpson, R Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Miller, Margaret A |e verfasserin |4 aut | |
| 700 | 1 | |a Girvin, Andrew T |e verfasserin |4 aut | |
| 700 | 1 | |a Taylor, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Williams, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a D'Antonio, Nelson |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Rajagopalan, Adhithi |e verfasserin |4 aut | |
| 700 | 1 | |a Flietner, Evan |e verfasserin |4 aut | |
| 700 | 1 | |a Wilson, Kelli |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xiaohu |e verfasserin |4 aut | |
| 700 | 1 | |a Shinn, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Klumpp-Thomas, Carleen |e verfasserin |4 aut | |
| 700 | 1 | |a McKnight, Crystal |e verfasserin |4 aut | |
| 700 | 1 | |a Itkin, Zina |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Lu |e verfasserin |4 aut | |
| 700 | 1 | |a Kazandijian, Dickran |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jing |e verfasserin |4 aut | |
| 700 | 1 | |a Michalowski, Aleksandra M |e verfasserin |4 aut | |
| 700 | 1 | |a Simmons, John K |e verfasserin |4 aut | |
| 700 | 1 | |a Keats, Jonathan |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Craig J |e verfasserin |4 aut | |
| 700 | 1 | |a Mock, Beverly A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer letters |d 1976 |g 568(2023) vom: 01. Aug., Seite 216284 |w (DE-627)NLM000147273 |x 1872-7980 |7 nnns |
| 773 | 1 | 8 | |g volume:568 |g year:2023 |g day:01 |g month:08 |g pages:216284 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.canlet.2023.216284 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 568 |j 2023 |b 01 |c 08 |h 216284 | ||